Pfizer and Moderna are developing a combination vaccine using mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus — and that’s a terrible idea, according to Dr. Peter McCullough and John Leake.
Recently both Pfizer and Moderna announced they were developing a combination injection utilizing mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus.
Because the COVID-19 component is under Emergency Use Authorization (EUA), has failed in animal studies and no human trials have been reported, that component should be off the table from the start.
A recent paper from Chemaitelly and colleagues demonstrated in the Omicron era, COVID-19 boosters had unacceptably low protection against acquiring the infection and no valid study has ever demonstrated reductions in hospitalizations and deaths.
To make matters worse, any theoretical benefit from a COVID-19 vaccine would last less than six months, so additional shots would be out of phase with the other component of the combination product.
mRNA coding for influenza would be a new biological product not under EUA so should have to go through the full five-year regulatory development cycle for genetic biologicals.